B7-33 dose range
The amounts people commonly use, from the low end to the high end, with syringe units, schedule and half-life. The 6 published studies are one click away.
Animal studies only Repair Also called single-chain relaxin-2 B-chain analogue, H2 relaxin B7-33
Common use ranges
From user guides and clinic write-ups. No drug label exists, and no study has tested these amounts in people. Poor. Vendor and community guides range from 100 mcg to 5 mg a day, all scaled from rat and mouse studies with no human data.
Sources disagree, or there are very few. The amounts below come from a small number of guides, and they do not line up well. Treat every number on this page as uncertain, and check each source yourself.
- Half-life
- Not on the site yet, being checked
- How it is taken
- subcutaneous injection
- How long people use it
- Usually 4 to 8 weeks.
- Mixing used for the units
- 5 mg vial + 2 mL water. 1 unit on a U-100 insulin syringe = 25 mcg.
Pick your vial size and how much water you add. The units below change to match.
5 mg vial + 2 mL water: 1 unit = 25 mcg
| Tier | Each dose | Syringe units5 mg vial + 2 mL water | How often | Schedule | Vial lastsat this tier |
|---|---|---|---|---|---|
| Starting [1] | 100 mcg | 4 units 0.04 mL | once a day | 100 mcg once a day, stepped up over several weeks | 6+ weeks |
| Typical [2] | 300 mcg | 12 units 0.12 mL | once a day | 200 to 400 mcg once a day | 16 days |
| Higher [3] | 750 mcg | 30 units 0.30 mL | once a day | 500 to 1000 mcg once a day or every other day | 6 days |
Good to know
- A short piece of relaxin-2.
- Only tested in animals. No human trial exists.
- Some guides split it into two shots a day because it clears fast.
Sources for these amounts
- Starting: MyPeptideMatch, B7-33 dosage guide
- Typical: MyPeptideMatch, B7-33 dosage guide
- Higher: Peptide Alchemist, B7-33
How long people use it: MyPeptideMatch, B7-33 dosage guide · Peptide Alchemist, B7-33
Take the B7-33 chart with you
Get a one-page printable chart for B7-33, with the syringe units for each vial and water mix. We can also email you when a new B7-33 study is published.
This page shows what labels, clinics and users report, and what studies gave. It is not medical advice and not a recommendation for anyone. Many of these compounds are not approved for human use. Check your own medicines and lab work with a licensed clinician before using anything.
See the science: 6 published studies
No human dose data. No published human study of B7-33 states an amount given. Every figure on this page comes from animal studies.
Amounts given to animals in studies
Read this first. No human study. Many animal studies used a constant-release pump under the skin, not daily shots. All work comes from a small group of linked labs.
Every study used for this page
Proof grade: Animal studies only. No human dose data has been published. Amounts are quoted as each study reported them. Where the abstract does not state an amount, the row says so.
| Study | Who was studied | Amount given, as reported | Route | How often | How long | What the authors reported |
|---|---|---|---|---|---|---|
| PMID 30155023Hossain et al, Chem Sci 2016 | Rat, heart attack model | 0.5 mg/kg/day (PMC full text) | Systemic, route not given in the passage read (PMC full text) | Continuous daily | 4 weeks (weeks 8 to 12 after injury) | Less heart scarring, similar to native relaxin |
| PMID 30155023Hossain et al, Chem Sci 2016, mouse models | Mouse, drug-induced heart damage, allergic airway disease and prostate tumor models | 0.25 mg/kg/day (heart, airway). 0.075 and 0.25 mg/kg/day (tumor) (PMC full text) | Pump under the skin (heart, tumor). Into the nose (airway) (PMC full text) | Continuous daily, or once a day | About 1 to 2 weeks | Prevented heart and lung scarring. Unlike relaxin, did not grow prostate tumors |
| PMID 28478069Marshall et al, Eur J Pharmacol 2017 | Rat, male Wistar | 13.3 mcg/kg | IV (tail vein) | One time | Measured 3 hours later | Improved blood vessel relaxation in gut arteries, like serelaxin |
| PMID 32295457Devarakonda et al, J Am Heart Assoc 2020 | Mouse, heart attack model (38 treated, 34 vehicle) | 0.25 mg/kg (PMC full text) | Into the belly (PMC full text) | One time, just before blood flow returned | Followed 24 hours and 7 days | Infarct size about halved (22% vs 45%), heart pumping kept |
| PMID 33908676Bhuiyan et al, FASEB J 2021 | Mouse, blocked-kidney fibrosis model | 0.25 mg/kg/day | NOT IN ABSTRACT | Daily | 7 days | New imaging platform picked up less kidney fibrosis with treatment |
| PMID 36753958Alam et al, Biomed Pharmacother 2023 | Mouse, drug-induced heart damage | 0.25 mg/kg/day | Under the skin | Daily | Days 7 to 14 after injury | Cut heart scarring, inflammation and muscle thickening as well as relaxin |
How to read the study numbers
- One study, one group. Each figure is what one team chose for its own participants or animals.
- Route matters. An amount given into a vein (IV) is not the same as the same amount under the skin, in the nose or by mouth.
- Animals are not small people. An animal amount is shown as the study gave it. It is not a human amount.
- Short studies. Many studies ran days or weeks. They do not show what happens over longer use.
Common questions
Is there a human dose for B7-33?
No published human study of B7-33 states an amount given. The figures on this page come from animal studies only.
Where do these B7-33 numbers come from?
From 6 published studies, each linked to its PubMed or ClinicalTrials.gov record. Every figure was checked against the study abstract or its open full text. Proof grade: Animal studies only.
Is this a recommendation for how much B7-33 to use?
No. This page shows the amounts reported by drug labels, clinics and users, next to what researchers gave in studies. It is not medical advice and not a recommendation for anyone. Talk to a licensed clinician before using any of it.